Personalised intervention for people with depression and severe COPD

George S. Alexopoulos , Dimitris N. Kiosses , Jo Anne Sirey , Dora Kanellopoulos , Richard S. Novitch , Samiran Ghosh , Joanna K. Seirup , Patrick J. Raue
  • Declaration of interest

    G.S.A. has received grant support from Forest Pharmaceuticals; has consulted to Hoffman-LaRoche, Lilly, Pfizer and Otsuka; and has served on speakers bureaux of AstraZeneca, Avenir, Forest, Merck, Novartis and Sunovion.

Abstract

Chronic obstructive pulmonary disease (COPD) is often complicated by depression and exemplifies the challenge in managing chronic illnesses that require active patient participation in care. In a clinical trial (NCT00151372), we compared a novel personalised intervention for depression and COPD (PID-C) targeting treatment adherence with treatment as usual (TAU). In 138 patients with major depression and severe COPD, PID-C led to a higher remission rate and a greater reduction in depressive symptoms and in dyspnoea-related disability than TAU over 28 weeks and 6 months after the last session. If replicated, PID-C may serve as a care model for patients with both depression and medical illnesses with a deteriorating course.

Footnotes

  • Funding

    NIMHR01 HLB071992, P30 MH068638, P30 MH085943 and the Sanchez Foundation. R.S.N. partially supported by a grant from the Will Rogers Institute.

View Full Text